Simon Messing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Simon Messing has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Dominic Esposito
Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
11 shared publications - Dhirendra K. Simanshu
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA
10 shared publications - Frank McCormick
University of California, San Francisco 9 Helen Diller Family Comprehensive Cancer Center San Francisco, California
9 shared publications - Dwight V. Nissley
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, USA
7 shared publications William Gillette
6 shared publicationsShelley Perkins
5 shared publications
Latest Publications
- 11 November 2026
- Published by Elsevier in Protein Expression and Purification
- Vol. 244
TwinStrep™ tag purification leads to differences in RAF1 RAS binding domain and cysteine-rich domain conformation
- 11 November 2026
- Published by Elsevier in Protein Expression and Purification
- Vol. 244
TwinStrep™ tag purification leads to differences in RAF1 RAS binding domain and cysteine-rich domain conformation
- Open Access
- 29 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS
Direct targeting of KRAS through the Switch-II pocket is an effective therapeutic strategy, but acquired resistance limits clinical benefit. We examine clinically observed resistance mutations (R68S, H95Q, Y96C, Y96D and Q99L) arising during KRAS G12C inhibitor therapy using biochemical, structural, computational and cellular approaches. Covalent and noncovalent binding measurements reveal mutation- and inhibitor-specific reductions in drug engagement across inhibitor classes. Structural analyses identify two principal resistance mechanisms: Type I, involving loss of key inhibitor contacts, and Type II, involving stabilization of pocket-occluding Switch-II conformations. Y96D exhibits both mechanisms through nucleotide-dependent non-native intramolecular interactions, whereas R68S primarily exhibits Type I resistance with modest Type II effects on pocket architecture and Switch-region dynamics. Y96C, H95Q and Q99L predominantly exhibit Type I resistance. All mutants retain RAF1 binding, whereas PI3Kα binding is selectively reduced by R68S and Q99L. Together, these findings provide structural insights for understanding on-target resistance to Switch-II pocket inhibitors.
- 29 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessStructural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS
Direct targeting of KRAS through the Switch-II pocket is an effective therapeutic strategy, but acquired resistance limits clinical benefit. We examine clinically observed resistance mutations (R68S, H95Q, Y96C, Y96D and Q99L) arising during KRAS G12C inhibitor therapy using biochemical, structural, computational and cellular approaches. Covalent and noncovalent binding measurements reveal mutation- and inhibitor-specific reductions in drug engagement across inhibitor classes. Structural analyses identify two principal resistance mechanisms: Type I, involving loss of key inhibitor contacts, and Type II, involving stabilization of pocket-occluding Switch-II conformations. Y96D exhibits both mechanisms through nucleotide-dependent non-native intramolecular interactions, whereas R68S primarily exhibits Type I resistance with modest Type II effects on pocket architecture and Switch-region dynamics. Y96C, H95Q and Q99L predominantly exhibit Type I resistance. All mutants retain RAF1 binding, whereas PI3Kα binding is selectively reduced by R68S and Q99L. Together, these findings provide structural insights for understanding on-target resistance to Switch-II pocket inhibitors.
- 15 May 2026
- Published by Elsevier in Protein Expression and Purification
- Vol. 242, 106950
High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study
- 15 May 2026
- Published by Elsevier in Protein Expression and Purification
- Vol. 242, 106950
High yield production of C-terminally processed KRAS4a, HRAS, and NRAS for biophysical study
- Open Access
- 30 March 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Disulfide tethering reveals cryptic pockets in oncogenic KRAS
Disulfide tethering is a site-directed method of drug discovery used to identify hits for challenging targets. We applied tethering to target oncogenic KRAS, a small GTPase once considered undruggable due to its high nucleotide affinity and a perceived absence of binding sites. We prepared a library of 2160 disulfide-containing fragments. We screened over 1000 compounds against a panel of 83 engineered cysteine mutants of KRAS G12D in the active conformation and screened the full library for a subset of 30 mutants. For select mutants and hits, we performed 2-mercaptoethanol competition assays (βME-50) to prioritize ligands. Ligandability analysis comparing hit rates across mutant residues enabled the identification of druggable hot spots. Our studies confirmed known binding sites, including the Switch-II / α-helix 3 pocket. In addition, we identified previously undescribed cryptic pockets and validated select hits using computational chemistry and NMR spectroscopy. These pockets represent promising opportunities for future drug discovery campaigns.
- 30 March 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Open AccessDisulfide tethering reveals cryptic pockets in oncogenic KRAS
Disulfide tethering is a site-directed method of drug discovery used to identify hits for challenging targets. We applied tethering to target oncogenic KRAS, a small GTPase once considered undruggable due to its high nucleotide affinity and a perceived absence of binding sites. We prepared a library of 2160 disulfide-containing fragments. We screened over 1000 compounds against a panel of 83 engineered cysteine mutants of KRAS G12D in the active conformation and screened the full library for a subset of 30 mutants. For select mutants and hits, we performed 2-mercaptoethanol competition assays (βME-50) to prioritize ligands. Ligandability analysis comparing hit rates across mutant residues enabled the identification of druggable hot spots. Our studies confirmed known binding sites, including the Switch-II / α-helix 3 pocket. In addition, we identified previously undescribed cryptic pockets and validated select hits using computational chemistry and NMR spectroscopy. These pockets represent promising opportunities for future drug discovery campaigns.
- 11 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6765) , 1112-1117
Structural basis for LZTR1 recognition of RAS GTPases for degradation
The RAS family of small guanosine triphosphatases (GTPases) are tightly regulated signaling molecules that are further modulated by ubiquitination and proteolysis. Leucine Zipper-like Transcription Regulator 1 (LZTR1), a substrate adapter of the Cullin-3 RING E3 ubiquitin ligase, binds specific RAS GTPases and promotes their ubiquitination and proteasomal degradation. We present structures of LZTR1 Kelch domains bound to RIT1, MRAS, and KRAS, revealing interfaces that govern RAS isoform selectivity and nucleotide specificity. Biochemical and structural analyses of disease-associated Kelch domain mutations revealed three types of alterations: impaired substrate interaction, loop destabilization, and blade-blade repulsion. In cellular and mouse models, mutations disrupting substrate binding phenocopied LZTR1 loss, underscoring its substrate specificity. These findings define RAS recognition mechanisms by LZTR1 and suggest a molecular glue strategy to degrade oncogenic KRAS.
- 11 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6765) , 1112-1117
Structural basis for LZTR1 recognition of RAS GTPases for degradation
The RAS family of small guanosine triphosphatases (GTPases) are tightly regulated signaling molecules that are further modulated by ubiquitination and proteolysis. Leucine Zipper-like Transcription Regulator 1 (LZTR1), a substrate adapter of the Cullin-3 RING E3 ubiquitin ligase, binds specific RAS GTPases and promotes their ubiquitination and proteasomal degradation. We present structures of LZTR1 Kelch domains bound to RIT1, MRAS, and KRAS, revealing interfaces that govern RAS isoform selectivity and nucleotide specificity. Biochemical and structural analyses of disease-associated Kelch domain mutations revealed three types of alterations: impaired substrate interaction, loop destabilization, and blade-blade repulsion. In cellular and mouse models, mutations disrupting substrate binding phenocopied LZTR1 loss, underscoring its substrate specificity. These findings define RAS recognition mechanisms by LZTR1 and suggest a molecular glue strategy to degrade oncogenic KRAS.
- Open Access
- 9 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (19)
Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
RAS is the most frequently mutated oncogene in cancer. RAS proteins show high sequence similarities in their G-domains but are significantly different in their C-terminal hypervariable regions (HVR). These regions interact with the cell membrane via lipid anchors that result from posttranslational modifications (PTM) of cysteine residues. KRAS4b is unique as it has only one cysteine that undergoes PTM, C185. Small molecule covalent modification of C185 would block any form of prenylation and subsequently inhibit attachment of KRAS4b to the cell membrane, blocking its biological activity. We translated this concept to the discovery and development of disulfide tethering screen hits into irreversible covalent modifiers of C185. These compounds inhibited proliferation of KRAS4b-driven mouse embryonic fibroblasts, but not cells driven by N-myristoylated KRAS4b that harbor a C185S mutation and are not dependent on C185 prenylation. Top–down proteomics was used to confirm target engagement in cells. These compounds bind in a pocket formed when the HVR folds back between helix 3 and 4 in the G-domain (HVR-α3-α4). This interaction can happen in the absence of small molecules as predicted by molecular dynamics simulations and is stabilized in the presence of C185 binders as confirmed by small-angle X-ray scattering and solution NMR. NOESY-HSQC, an NMR approach that measures internuclear distances of 6 Å or less, and structure analysis identified the critical residues and interactions that define the HVR-α3-α4 pocket. Further development of compounds that bind to this pocket could be the basis of a new approach to targeting KRAS cancers.
- 9 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (19)
Open AccessBlocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine
RAS is the most frequently mutated oncogene in cancer. RAS proteins show high sequence similarities in their G-domains but are significantly different in their C-terminal hypervariable regions (HVR). These regions interact with the cell membrane via lipid anchors that result from posttranslational modifications (PTM) of cysteine residues. KRAS4b is unique as it has only one cysteine that undergoes PTM, C185. Small molecule covalent modification of C185 would block any form of prenylation and subsequently inhibit attachment of KRAS4b to the cell membrane, blocking its biological activity. We translated this concept to the discovery and development of disulfide tethering screen hits into irreversible covalent modifiers of C185. These compounds inhibited proliferation of KRAS4b-driven mouse embryonic fibroblasts, but not cells driven by N-myristoylated KRAS4b that harbor a C185S mutation and are not dependent on C185 prenylation. Top–down proteomics was used to confirm target engagement in cells. These compounds bind in a pocket formed when the HVR folds back between helix 3 and 4 in the G-domain (HVR-α3-α4). This interaction can happen in the absence of small molecules as predicted by molecular dynamics simulations and is stabilized in the presence of C185 binders as confirmed by small-angle X-ray scattering and solution NMR. NOESY-HSQC, an NMR approach that measures internuclear distances of 6 Å or less, and structure analysis identified the critical residues and interactions that define the HVR-α3-α4 pocket. Further development of compounds that bind to this pocket could be the basis of a new approach to targeting KRAS cancers.
- Top Cited PapersOpen Access
- 9 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation
Mutations in RAS and PI3Kα are major drivers of human cancer. Their interaction plays a crucial role in activating PI3Kα and amplifying the PI3K-AKT-mTOR pathway. Disrupting RAS-PI3Kα interaction enhances survival in lung and skin cancer models and reduces tumor growth and angiogenesis, although the structural details of this interaction remain unclear. Here, we present structures of KRAS, RRAS2, and MRAS bound to the catalytic subunit (p110α) of PI3Kα, elucidating the interaction interfaces and local conformational changes upon complex formation. Structural and mutational analyses highlighted key residues in RAS and PI3Kα impacting binding affinity and revealed isoform-specific differences at the interaction interface in RAS and PI3K isoforms, providing a rationale for their differential affinities. Notably, in the RAS-p110α complex structures, RAS interaction with p110α is limited to the RAS-binding domain and does not involve the kinase domain. This study underscores the pivotal role of the RAS-PI3Kα interaction in PI3Kα activation and provides a blueprint for designing PI3Kα isoform-specific inhibitors to disrupt this interaction.
- 9 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Top Cited PapersOpen AccessStructural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation
Mutations in RAS and PI3Kα are major drivers of human cancer. Their interaction plays a crucial role in activating PI3Kα and amplifying the PI3K-AKT-mTOR pathway. Disrupting RAS-PI3Kα interaction enhances survival in lung and skin cancer models and reduces tumor growth and angiogenesis, although the structural details of this interaction remain unclear. Here, we present structures of KRAS, RRAS2, and MRAS bound to the catalytic subunit (p110α) of PI3Kα, elucidating the interaction interfaces and local conformational changes upon complex formation. Structural and mutational analyses highlighted key residues in RAS and PI3Kα impacting binding affinity and revealed isoform-specific differences at the interaction interface in RAS and PI3K isoforms, providing a rationale for their differential affinities. Notably, in the RAS-p110α complex structures, RAS interaction with p110α is limited to the RAS-binding domain and does not involve the kinase domain. This study underscores the pivotal role of the RAS-PI3Kα interaction in PI3Kα activation and provides a blueprint for designing PI3Kα isoform-specific inhibitors to disrupt this interaction.
- 15 December 2024
- Published by Elsevier in Protein Expression and Purification
- Vol. 228, 106648
Improvements in large-scale production of tobacco etch virus protease
- 15 December 2024
- Published by Elsevier in Protein Expression and Purification
- Vol. 228, 106648
Improvements in large-scale production of tobacco etch virus protease
- 22 August 2024
- Published by Elsevier in Protein Expression and Purification
- Vol. 225, 106582
Improved production of class I phosphatidylinositol 4,5-bisphosphate 3-kinase
- 22 August 2024
- Published by Elsevier in Protein Expression and Purification
- Vol. 225, 106582
Improved production of class I phosphatidylinositol 4,5-bisphosphate 3-kinase